免疫检查点抑制剂治疗免疫相关不良反应的血液和组织病理学生物标志物

Yogesh Jheengut, Y. Liu, Ling Liu
{"title":"免疫检查点抑制剂治疗免疫相关不良反应的血液和组织病理学生物标志物","authors":"Yogesh Jheengut, Y. Liu, Ling Liu","doi":"10.34175/jno201904002","DOIUrl":null,"url":null,"abstract":"Corresponding author: Ling Xiang Liu, MD, PhD, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd., Nanjing, Jiangsu 210029, China; Tel: +86 25 6830 6714; Email: llxlau@163.com. Introduction Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1) antibodies and anti-programmed cell death 1 ligand (PDL1) antibodies are immune checkpoint inhibitors (ICI) currently being used for the treatment of many cancers, including metastatic melanoma, non-small cell lung carcinoma, renal cell carcinoma and colorectal cancer. The ICI can be used either alone or in combination with other therapies. However, by disrupting the balance or the control of the immune system, these immune checkpoint inhibitors, can also generate autoimmune toxicities, which mainly involve the gut, skin, endocrine glands, liver, and lungs, but can affect any tissue. This review, provides an overview of the latest and most relevant blood and histopathological biomarkers which can be used to predict or detect the organ specific adverse effects following the use of ICI. Where appropriate, other biomarkers that can be used to detect or predict organ specific adverse effects are described.","PeriodicalId":64349,"journal":{"name":"Journal of Nutritional Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Blood and Histopathological Biomarkers of Immune-related Adverse Effects of Treatment with Immune \\nCheckpoint Inhibitors\",\"authors\":\"Yogesh Jheengut, Y. Liu, Ling Liu\",\"doi\":\"10.34175/jno201904002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Corresponding author: Ling Xiang Liu, MD, PhD, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd., Nanjing, Jiangsu 210029, China; Tel: +86 25 6830 6714; Email: llxlau@163.com. Introduction Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1) antibodies and anti-programmed cell death 1 ligand (PDL1) antibodies are immune checkpoint inhibitors (ICI) currently being used for the treatment of many cancers, including metastatic melanoma, non-small cell lung carcinoma, renal cell carcinoma and colorectal cancer. The ICI can be used either alone or in combination with other therapies. However, by disrupting the balance or the control of the immune system, these immune checkpoint inhibitors, can also generate autoimmune toxicities, which mainly involve the gut, skin, endocrine glands, liver, and lungs, but can affect any tissue. This review, provides an overview of the latest and most relevant blood and histopathological biomarkers which can be used to predict or detect the organ specific adverse effects following the use of ICI. Where appropriate, other biomarkers that can be used to detect or predict organ specific adverse effects are described.\",\"PeriodicalId\":64349,\"journal\":{\"name\":\"Journal of Nutritional Oncology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nutritional Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.34175/jno201904002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutritional Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.34175/jno201904002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

通讯作者:刘凌翔,医学博士,南京医科大学第一附属医院肿瘤科,江苏南京广州路300号,江苏南京210029;电话:+86 25 6830 6714;电子邮件:llxlau@163.com。抗细胞毒性t淋巴细胞相关蛋白4 (CTLA-4)、抗程序性细胞死亡蛋白1 (PD-1)抗体和抗程序性细胞死亡1配体(PDL1)抗体是免疫检查点抑制剂(ICI),目前被用于治疗许多癌症,包括转移性黑色素瘤、非小细胞肺癌、肾细胞癌和结直肠癌。ICI既可以单独使用,也可以与其他疗法联合使用。然而,通过破坏免疫系统的平衡或控制,这些免疫检查点抑制剂也可以产生自身免疫性毒性,主要涉及肠道、皮肤、内分泌腺、肝脏和肺部,但可以影响任何组织。本文综述了最新和最相关的血液和组织病理学生物标志物,这些生物标志物可用于预测或检测使用ICI后器官特异性不良反应。在适当的情况下,描述了可用于检测或预测器官特异性不良反应的其他生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Blood and Histopathological Biomarkers of Immune-related Adverse Effects of Treatment with Immune Checkpoint Inhibitors
Corresponding author: Ling Xiang Liu, MD, PhD, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd., Nanjing, Jiangsu 210029, China; Tel: +86 25 6830 6714; Email: llxlau@163.com. Introduction Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1) antibodies and anti-programmed cell death 1 ligand (PDL1) antibodies are immune checkpoint inhibitors (ICI) currently being used for the treatment of many cancers, including metastatic melanoma, non-small cell lung carcinoma, renal cell carcinoma and colorectal cancer. The ICI can be used either alone or in combination with other therapies. However, by disrupting the balance or the control of the immune system, these immune checkpoint inhibitors, can also generate autoimmune toxicities, which mainly involve the gut, skin, endocrine glands, liver, and lungs, but can affect any tissue. This review, provides an overview of the latest and most relevant blood and histopathological biomarkers which can be used to predict or detect the organ specific adverse effects following the use of ICI. Where appropriate, other biomarkers that can be used to detect or predict organ specific adverse effects are described.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
154
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信